-
Media Release
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
-
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media Release
NEJM published study shows Novartis compound ACZ885 significantly relieves symptoms in patients with serious form of childhood arthritis
-
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Multimedia Assets: Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
-
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media Release
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media Release
Leeza Gibbons joins Novartis to improve caregiving experience for millions of Americans through real-world peer advice on AlzheimersDisease.com
-
Media Release
Novartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer